Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove, OSI to Offer Combination of Drug Discovery Platforms

NEW YORK (GenomeWeb News) – BioTrove said today that it has teamed up with OSI Pharmaceuticals to offer customers a combination of the firm’s drug discovery platforms.
The alliance will offer OSI’s Integrated Lead Discovery Platform with BioTrove’s RapidFire mass spectrometry-based assay development, screening, and analysis services. The OSI platform enables screening of large volumes of compounds against target assays, while the RapidFire platform enables label-free, high-throughput screening using biological substrates to identify active compounds within chemical libraries.
The companies expect that the combined tools will “enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale, high-throughput screening internally,” said BioTrove President and CEO Albert Luderer in a statement.
Financial terms of the alliance were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.